Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa

A phase II study of the AIDS malignancy consortium

Mark H. Einstein, Ntokozo Ndlovu, Jeannette Lee, Elizabeth A. Stier, Jeffrey Kotzen, Madhur K. Garg, Kathleen D. Whitney, Shelly Y. Lensing, Mariza Tunmer, Webster Kadzatsa, Joel Palefsky, Susan E. Krown

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART). Patients and methods: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41.4–45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2 and were followed for 12 months. Results: Sixty-four women were screened at two sites in sub-Saharan Africa, of whom 40 eligible participants were enrolled, for a screening ratio of 1.60. Of the 38 eligible participants who initiated study treatment, 31 (82%) completed treatment. By the 12-month follow-up visit, 7 women had died of disease and 29 of 31 (94%) returned for follow-up. One-year progression-free survival was 76.3% (95% CI, 59.4–86.9%), and did not significantly differ according to stage at entry (p = 0.581). Participant-reported adherence to ART was high; by 12 months, 93% of participants had an undetectable viral load. The most common grade 3 or 4 adverse event was decreased lymphocyte count that affected all treated participants. Non-hematologic serious adverse events were similar to those observed in women with LACC without HIV infection. Conclusions: The majority of HIV-infected women with LACC can complete concomitant chemoradiotherapy with the same cisplatin dose used in HIV-uninfected women with comparable tolerability and high ART adherence while on treatment.

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Africa South of the Sahara
Uterine Cervical Neoplasms
Cisplatin
Acquired Immunodeficiency Syndrome
Radiotherapy
HIV
Neoplasms
Chemoradiotherapy
HIV Infections
Therapeutics
Brachytherapy
Lymphocyte Count
Viral Load
Cervix Uteri
Disease-Free Survival
Carcinoma
Safety

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa : A phase II study of the AIDS malignancy consortium. / Einstein, Mark H.; Ndlovu, Ntokozo; Lee, Jeannette; Stier, Elizabeth A.; Kotzen, Jeffrey; Garg, Madhur K.; Whitney, Kathleen D.; Lensing, Shelly Y.; Tunmer, Mariza; Kadzatsa, Webster; Palefsky, Joel; Krown, Susan E.

In: Gynecologic Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Einstein, Mark H. ; Ndlovu, Ntokozo ; Lee, Jeannette ; Stier, Elizabeth A. ; Kotzen, Jeffrey ; Garg, Madhur K. ; Whitney, Kathleen D. ; Lensing, Shelly Y. ; Tunmer, Mariza ; Kadzatsa, Webster ; Palefsky, Joel ; Krown, Susan E. / Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa : A phase II study of the AIDS malignancy consortium. In: Gynecologic Oncology. 2019.
@article{69657f68a74948e2be17dbd15792ea94,
title = "Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium",
abstract = "Purpose: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART). Patients and methods: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41.4–45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2 and were followed for 12 months. Results: Sixty-four women were screened at two sites in sub-Saharan Africa, of whom 40 eligible participants were enrolled, for a screening ratio of 1.60. Of the 38 eligible participants who initiated study treatment, 31 (82{\%}) completed treatment. By the 12-month follow-up visit, 7 women had died of disease and 29 of 31 (94{\%}) returned for follow-up. One-year progression-free survival was 76.3{\%} (95{\%} CI, 59.4–86.9{\%}), and did not significantly differ according to stage at entry (p = 0.581). Participant-reported adherence to ART was high; by 12 months, 93{\%} of participants had an undetectable viral load. The most common grade 3 or 4 adverse event was decreased lymphocyte count that affected all treated participants. Non-hematologic serious adverse events were similar to those observed in women with LACC without HIV infection. Conclusions: The majority of HIV-infected women with LACC can complete concomitant chemoradiotherapy with the same cisplatin dose used in HIV-uninfected women with comparable tolerability and high ART adherence while on treatment.",
author = "Einstein, {Mark H.} and Ntokozo Ndlovu and Jeannette Lee and Stier, {Elizabeth A.} and Jeffrey Kotzen and Garg, {Madhur K.} and Whitney, {Kathleen D.} and Lensing, {Shelly Y.} and Mariza Tunmer and Webster Kadzatsa and Joel Palefsky and Krown, {Susan E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2019.01.023",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa

T2 - A phase II study of the AIDS malignancy consortium

AU - Einstein, Mark H.

AU - Ndlovu, Ntokozo

AU - Lee, Jeannette

AU - Stier, Elizabeth A.

AU - Kotzen, Jeffrey

AU - Garg, Madhur K.

AU - Whitney, Kathleen D.

AU - Lensing, Shelly Y.

AU - Tunmer, Mariza

AU - Kadzatsa, Webster

AU - Palefsky, Joel

AU - Krown, Susan E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART). Patients and methods: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41.4–45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2 and were followed for 12 months. Results: Sixty-four women were screened at two sites in sub-Saharan Africa, of whom 40 eligible participants were enrolled, for a screening ratio of 1.60. Of the 38 eligible participants who initiated study treatment, 31 (82%) completed treatment. By the 12-month follow-up visit, 7 women had died of disease and 29 of 31 (94%) returned for follow-up. One-year progression-free survival was 76.3% (95% CI, 59.4–86.9%), and did not significantly differ according to stage at entry (p = 0.581). Participant-reported adherence to ART was high; by 12 months, 93% of participants had an undetectable viral load. The most common grade 3 or 4 adverse event was decreased lymphocyte count that affected all treated participants. Non-hematologic serious adverse events were similar to those observed in women with LACC without HIV infection. Conclusions: The majority of HIV-infected women with LACC can complete concomitant chemoradiotherapy with the same cisplatin dose used in HIV-uninfected women with comparable tolerability and high ART adherence while on treatment.

AB - Purpose: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART). Patients and methods: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41.4–45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2 and were followed for 12 months. Results: Sixty-four women were screened at two sites in sub-Saharan Africa, of whom 40 eligible participants were enrolled, for a screening ratio of 1.60. Of the 38 eligible participants who initiated study treatment, 31 (82%) completed treatment. By the 12-month follow-up visit, 7 women had died of disease and 29 of 31 (94%) returned for follow-up. One-year progression-free survival was 76.3% (95% CI, 59.4–86.9%), and did not significantly differ according to stage at entry (p = 0.581). Participant-reported adherence to ART was high; by 12 months, 93% of participants had an undetectable viral load. The most common grade 3 or 4 adverse event was decreased lymphocyte count that affected all treated participants. Non-hematologic serious adverse events were similar to those observed in women with LACC without HIV infection. Conclusions: The majority of HIV-infected women with LACC can complete concomitant chemoradiotherapy with the same cisplatin dose used in HIV-uninfected women with comparable tolerability and high ART adherence while on treatment.

UR - http://www.scopus.com/inward/record.url?scp=85061566648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061566648&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2019.01.023

DO - 10.1016/j.ygyno.2019.01.023

M3 - Article

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -